Breakingviews TV: Biogen fail

The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.

from Reuters Video: Breakingviews https://ift.tt/2HKoSJH